PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect.

[1]  Mark Voorneveld,et al.  Preparation , 2018, Games Econ. Behav..

[2]  Murali M. Yallapu,et al.  Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. , 2010, Journal of colloid and interface science.

[3]  S. Feng,et al.  Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. , 2010, Journal of pharmaceutical sciences.

[4]  J. Panyam,et al.  Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention. , 2010, Cancer research.

[5]  Chandana Mohanty,et al.  Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. , 2010, Biomaterials.

[6]  Hiroshi Maeda,et al.  Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. , 2010, Bioconjugate chemistry.

[7]  张华,et al.  雷帕霉素聚乳酸-聚乙醇酸共聚物纳米粒子对人脐动脉平滑肌细胞细胞周期时相、p27蛋白表达及细胞增殖的影响 , 2010 .

[8]  J. Kreuter,et al.  Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[9]  B. Aggarwal,et al.  Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. , 2010, Biochemical pharmacology.

[10]  C. Tros de Ilarduya,et al.  Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice. , 2010, European journal of pharmaceutics and biopharmaceutics.

[11]  S. Sahoo,et al.  Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  Christine Jérôme,et al.  Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Fahima Dilnawaz,et al.  Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. , 2009, Biomaterials.

[14]  Liang Zhou,et al.  In-vitro evaluation of paclitaxel-loaded MPEG–PLGA nanoparticles on laryngeal cancer cells , 2009, Anti-cancer drugs.

[15]  J. Vishwanatha,et al.  Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. , 2009, Anticancer research.

[16]  C. Yeh,et al.  Paclitaxel‐Loaded Stabilizer‐Free Poly(D,L‐lactide‐co‐glycolide) Nanoparticles Conjugated with Quantum Dots for Reversion of Anti‐Cancer Drug Resistance and Cancer Cellular Imaging , 2009 .

[17]  Shiaw-Min Hwang,et al.  Stabilizer-Free Poly(lactide-co-glycolide) Nanoparticles Conjugated with Quantum Dots as a Potential Carrier Applied in Human Mesenchymal Stem Cells , 2009 .

[18]  Kyung-Hwa Yoo,et al.  Multifunctional nanoparticles for combined doxorubicin and photothermal treatments. , 2009, ACS nano.

[19]  C. Lehr,et al.  PLGA Nanoparticles Stabilized with Cationic Surfactant: Safety Studies and Application in Oral Delivery of Paclitaxel to Treat Chemical-Induced Breast Cancer in Rat , 2009, Pharmaceutical Research.

[20]  Xiangrong Song,et al.  Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[21]  M. R. Kumar,et al.  Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  William B. Krantz,et al.  Hydrogel Matrix Entrapping PLGA-Paclitaxel Microspheres: Drug Delivery with Near Zero-Order Release and Implantability Advantages for Malignant Brain Tumour Chemotherapy , 2009, Pharmaceutical Research.

[23]  Lai Yeng Lee,et al.  Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. , 2009, Biomaterials.

[24]  J. Panyam,et al.  Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[25]  Peter H Lin,et al.  Current advances in research and clinical applications of PLGA-based nanotechnology , 2009, Expert review of molecular diagnostics.

[26]  Wenjie Song,et al.  Cytotoxicity of Paclitaxel Incorporated in PLGA Nanoparticles on Hypoxic Human Tumor Cells , 2009, Pharmaceutical Research.

[27]  Zhuo Georgia Chen,et al.  Advances of cancer therapy by nanotechnology. , 2009, Cancer research and treatment : official journal of Korean Cancer Association.

[28]  N. Zhang,et al.  Studies on bioadhesive PLGA nanoparticles: A promising gene delivery system for efficient gene therapy to lung cancer. , 2009, International journal of pharmaceutics.

[29]  M. Foti,et al.  Dexamethasone-containing PLGA superparamagnetic microparticles as carriers for the local treatment of arthritis. , 2009, Biomaterials.

[30]  H. Maeda,et al.  Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[31]  G. Sharma,et al.  Design of Biodegradable Nanoparticles for Oral Delivery of Doxorubicin: In vivo Pharmacokinetics and Toxicity Studies in Rats , 2009, Pharmaceutical Research.

[32]  M. Roberts,et al.  In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[33]  S. Baratchi,et al.  Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases , 2009 .

[34]  Robert Langer,et al.  Impact of nanotechnology on drug delivery. , 2009, ACS nano.

[35]  Christine Jérôme,et al.  Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[36]  G. Navarro,et al.  In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma , 2009, The journal of gene medicine.

[37]  N. Zhang,et al.  New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles , 2009, Drug delivery.

[38]  F. Shirazi,et al.  9-Nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats , 2008, Anti-cancer drugs.

[39]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[40]  Patrick Soon-Shiong,et al.  Protein nanoparticles as drug carriers in clinical medicine. , 2008, Advanced drug delivery reviews.

[41]  Dar-Bin Shieh,et al.  Stabilizer-free poly(lactide-co-glycolide) nanoparticles for multimodal biomedical probes. , 2008, Biomaterials.

[42]  Inga Cicenaite,et al.  Composition of PLGA and PEI/DNA nanoparticles improves ultrasound-mediated gene delivery in solid tumors in vivo. , 2008, Cancer letters.

[43]  J. Shapiro,et al.  Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. , 2008, Journal of biomedical materials research. Part A.

[44]  Xu Wang,et al.  Application of Nanotechnology in Cancer Therapy and Imaging , 2008, CA: a cancer journal for clinicians.

[45]  Xiangrong Song,et al.  PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. , 2008, International journal of pharmaceutics.

[46]  Tejraj M Aminabhavi,et al.  Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[47]  S. Krishnakumar,et al.  Nanotechnology in ocular drug delivery. , 2008, Drug discovery today.

[48]  Y. Wang,et al.  Formulation of Superparamagnetic Iron Oxides by Nanoparticles of Biodegradable Polymers for Magnetic Resonance Imaging , 2008 .

[49]  Manmohan J. Singh,et al.  A comparison of anionic nanoparticles and microparticles as vaccine delivery systems , 2008, Human vaccines.

[50]  A. Babbar,et al.  Etoposide Loaded PLGA and PCL Nanoparticles II: Biodistribution and Pharmacokinetics after Radiolabeling with Tc-99m , 2008 .

[51]  S. Parveen,et al.  Polymeric nanoparticles for cancer therapy , 2008, Journal of drug targeting.

[52]  N. Robert,et al.  Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. , 2007, Clinical breast cancer.

[53]  H. Fenniri,et al.  Nanotechnology-based drug delivery systems , 2007, Journal of occupational medicine and toxicology.

[54]  Robert A Newman,et al.  Bioavailability of curcumin: problems and promises. , 2007, Molecular pharmaceutics.

[55]  H. Okada,et al.  Spray-drying preparation of microparticles containing cationic PLGA nanospheres as gene carriers for avoiding aggregation of nanospheres. , 2007, International journal of pharmaceutics.

[56]  Shuming Nie,et al.  Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry , 2007, Nature Protocols.

[57]  G. Feldmann,et al.  Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy , 2007, Journal of nanobiotechnology.

[58]  R. Weissleder,et al.  Targeted delivery of multifunctional magnetic nanoparticles. , 2007, Nanomedicine.

[59]  Lisa Brannon-Peppas,et al.  Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. , 2007, Nanomedicine.

[60]  J. Panda,et al.  The present and future of nanotechnology in human health care. , 2007, Nanomedicine : nanotechnology, biology, and medicine.

[61]  Gian Franco Gensini,et al.  The contributions of Paul Ehrlich to infectious disease. , 2007, Journal of Infection.

[62]  Elias Fattal,et al.  Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. , 2007, International journal of pharmaceutics.

[63]  M. Sawyer,et al.  Pharmacogenetics of paclitaxel metabolism. , 2007, Critical reviews in oncology/hematology.

[64]  Daniel S Kohane,et al.  Microparticles and nanoparticles for drug delivery. , 2007, Biotechnology and bioengineering.

[65]  Diane J Burgess,et al.  Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[66]  Flemming Forsberg,et al.  Comparison of in vitro and in vivo acoustic response of a novel 50:50 PLGA contrast agent. , 2006, Ultrasonics.

[67]  Ruth Duncan,et al.  Polymer conjugates as anticancer nanomedicines , 2006, Nature Reviews Cancer.

[68]  Wei Liu,et al.  Preparation and characterization of novel CdSe quantum dots modified with poly (d, l-lactide) nanoparticles , 2006 .

[69]  R. Mumper,et al.  In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[70]  B. Gander,et al.  One-step preparation of polyelectrolyte-coated PLGA microparticles and their functionalization with model ligands. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[71]  Shimon Weiss,et al.  Advances in fluorescence imaging with quantum dot bio-probes. , 2006, Biomaterials.

[72]  Mansoor M Amiji,et al.  Multi-functional polymeric nanoparticles for tumour-targeted drug delivery , 2006, Expert opinion on drug delivery.

[73]  You Han Bae,et al.  Polymer Architecture and Drug Delivery , 2006, Pharmaceutical Research.

[74]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[75]  D. Bodkin,et al.  Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study. , 2005, Clinical lung cancer.

[76]  J. Sludden,et al.  A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules , 2005, Clinical Cancer Research.

[77]  Chi-Hwa Wang,et al.  Self-Assembled Biodegradable Nanoparticles Developed by Direct Dialysis for the Delivery of Paclitaxel , 2005, Pharmaceutical Research.

[78]  Wolfgang Eiermann,et al.  Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  S. Sahoo,et al.  Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. , 2005, Molecular pharmaceutics.

[80]  Vladimir P Torchilin,et al.  Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo , 2005, Nature Medicine.

[81]  D. W. van der Weide,et al.  Colloidal quantum dots initiating current bursts in lipid bilayers. , 2005, Biosensors & bioelectronics.

[82]  Xiao Zhou,et al.  Preparation and evaluation of poly(L-lactide-co-glycolide) (PLGA) microbubbles as a contrast agent for myocardial contrast echocardiography. , 2005, Journal of biomedical materials research. Part B, Applied biomaterials.

[83]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[84]  E. Allémann,et al.  Poly(D,L-lactide-co-glycolide) protein-loaded nanoparticles prepared by the double emulsion method—processing and formulation issues for enhanced entrapment efficiency , 2005, Journal of microencapsulation.

[85]  J. Kos,et al.  Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells. , 2004, Experimental cell research.

[86]  S. Sahoo,et al.  Efficacy of transferrin‐conjugated paclitaxel‐loaded nanoparticles in a murine model of prostate cancer , 2004, International journal of cancer.

[87]  R. Murthy,et al.  Etoposide-incorporated tripalmitin nanoparticles with different surface charge: Formulation, characterization, radiolabeling, and biodistribution studies , 2004, The AAPS Journal.

[88]  S. Nie,et al.  In vivo cancer targeting and imaging with semiconductor quantum dots , 2004, Nature Biotechnology.

[89]  D. Bissett,et al.  Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT) , 2004, British Journal of Cancer.

[90]  J. Gligorov,et al.  Preclinical pharmacology of the taxanes: implications of the differences. , 2004, The oncologist.

[91]  H. Onishi,et al.  Antitumor characteristics of methoxypolyethylene glycol-poly(DL-lactic acid) nanoparticles containing camptothecin. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[92]  V. Labhasetwar,et al.  Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. , 2004, Molecular pharmaceutics.

[93]  G. Mills,et al.  Determinants of Rapamycin Sensitivity in Breast Cancer Cells , 2004, Clinical Cancer Research.

[94]  Si-Shen Feng,et al.  Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. , 2004, Current medicinal chemistry.

[95]  V. Labhasetwar,et al.  Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. , 2004, Molecular pharmaceutics.

[96]  J. Irache,et al.  Fluconazole encapsulation in PLGA microspheres by spray-drying , 2004, Journal of microencapsulation.

[97]  S. Sahoo,et al.  Nanotech approaches to drug delivery and imaging. , 2003, Drug discovery today.

[98]  C. Galmarini,et al.  Multidrug resistance in cancer therapy: role of the microenvironment. , 2003, Current opinion in investigational drugs.

[99]  Chava Kimchi-Sarfaty,et al.  P-glycoprotein: from genomics to mechanism , 2003, Oncogene.

[100]  C. Bréchot,et al.  Gene therapy of hepatocarcinoma: a long way from the concept to the therapeutical impact , 2003, Cancer Gene Therapy.

[101]  Jayanth Panyam,et al.  Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles. , 2003, International journal of pharmaceutics.

[102]  M. Rocchetti,et al.  Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma , 2003, Cancer Chemotherapy and Pharmacology.

[103]  R. Schall,et al.  Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer , 2003, BJU international.

[104]  M. Blagosklonny.  Targeting cancer cells by exploiting their resistance. , 2003, Trends in molecular medicine.

[105]  Z. Ram,et al.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.

[106]  Jun Fang,et al.  Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. , 2003, International immunopharmacology.

[107]  Jayanth Panyam,et al.  Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.

[108]  M. D'souza,et al.  Evaluation of PLGA Microspheres as Delivery System for Antitumor Agent-Camptothecin , 2003, Drug development and industrial pharmacy.

[109]  T. Gardner,et al.  Diabetic retinopathy: more than meets the eye. , 2002, Survey of ophthalmology.

[110]  S. Simões,et al.  Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[111]  V. Labhasetwar,et al.  Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. , 2002, International journal of pharmaceutics.

[112]  H. Lee,et al.  Synthesis of Pegylated Immunonanoparticles , 2002, Pharmaceutical Research.

[113]  Jayanth Panyam,et al.  Rapid endo‐lysosomal escape of poly(DL‐lactide‐coglycolide) nanoparticles: implications for drug and gene delivery , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[114]  S. Sahoo,et al.  Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[115]  A. Karydas,et al.  PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[116]  S. Nie,et al.  Luminescent quantum dots for multiplexed biological detection and imaging. , 2002, Current opinion in biotechnology.

[117]  A. Vila,et al.  Design of biodegradable particles for protein delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[118]  K. Garber.  Rapamycin may prevent post-transplant lymphoma. , 2001, Journal of the National Cancer Institute.

[119]  James M. Anderson,et al.  Biological Responses to Materials , 2001 .

[120]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[121]  B. Casto,et al.  Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model. , 2001, Anticancer research.

[122]  David J Brayden,et al.  Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. , 2001, Vaccine.

[123]  S. Yalkowsky,et al.  Solubilization of rapamycin. , 2001, International journal of pharmaceutics.

[124]  M. Ishitobi,et al.  Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel , 2001, International Journal of Clinical Oncology.

[125]  M. Hidalgo,et al.  The rapamycin-sensitive signal transduction pathway as a target for cancer therapy , 2000, Oncogene.

[126]  P. Baldrick.  Pharmaceutical excipient development: the need for preclinical guidance. , 2000, Regulatory toxicology and pharmacology : RTP.

[127]  L. Mayer,et al.  Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[128]  T. Park,et al.  In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[129]  T. Kissel,et al.  Sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide)s facilitate the preparation of small negatively charged biodegradable nanospheres. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[130]  J. Thigpen.  Chemotherapy for advanced ovarian cancer: overview of randomized trials. , 2000, Seminars in oncology.

[131]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[132]  Y. Kano,et al.  Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors , 2000, Cancer Gene Therapy.

[133]  E. Jones,et al.  HLA-B27 and disease pathogenesis: new structural and functional insights , 1999, Expert Reviews in Molecular Medicine.

[134]  R. Brown,et al.  Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs , 1999, Expert Reviews in Molecular Medicine.

[135]  R. Panchagnula,et al.  Localized paclitaxel delivery. , 1999, International journal of pharmaceutics.

[136]  T. Park,et al.  Biodegradable Nanoparticles Containing Doxorubicin-PLGA Conjugate for Sustained Release , 1999, Pharmaceutical Research.

[137]  Jen-kun Lin,et al.  Biotransformation of curcumin through reduction and glucuronidation in mice. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[138]  E. Hersh,et al.  Cationic lipid-mediated gene transfer: current concepts. , 1999, Current opinion in molecular therapeutics.

[139]  S. Davis,et al.  PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[140]  Y. Pommier,et al.  Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. , 1998, Biochimica et biophysica acta.

[141]  Hiroshi Maeda,et al.  Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues , 1998, Japanese journal of cancer research : Gann.

[142]  G. Garcı́a-Cardeña,et al.  Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. , 1997, The Journal of clinical investigation.

[143]  I. Verma,et al.  Gene therapy - promises, problems and prospects , 1997, Nature.

[144]  J. Peponis.  Formulation , 1997, Karaite Marriage Contracts from the Cairo Geniza.

[145]  D. Huhn,et al.  Preclinical experiences with magnetic drug targeting: tolerance and efficacy. , 1996, Cancer research.

[146]  P Reichardt,et al.  Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. , 1996, Cancer research.

[147]  Donald L. Wise,et al.  Encyclopedic Handbook of Biomaterials and Bioengineering , 1995 .

[148]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.

[149]  Lisa Brannon-Peppas,et al.  Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery , 1995 .

[150]  Allan G. A. Coombes,et al.  Surface Modification of Poly(lactide-co-glycolide) Nanospheres by Biodegradable Poly(lactide)-Poly(ethylene glycol) Copolymers , 1994, Pharmaceutical Research.

[151]  H. Maeda,et al.  Enhanced Vascular Permeability in Solid Tumor Is Mediated by Nitric Oxide and Inhibited by Both New Nitric Oxide Scavenger and Nitric Oxide Synthase Inhibitor , 1994, Japanese journal of cancer research : Gann.

[152]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[153]  T. Konno.  Targeting chemotherapy for hepatoma: arterial administration of anticancer drugs dissolved in Lipiodol. , 1992, European journal of cancer.

[154]  H. Maeda,et al.  SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. , 1991, Advanced drug delivery reviews.

[155]  H. Maeda,et al.  Comparison of the cytotoxic effects of the high- and low-molecular-weight anticancer agents on multidrug-resistant Chinese hamster ovary cells in vitro. , 1990, Cancer research.

[156]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[157]  L. Liu,et al.  DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. , 1989, Science.

[158]  H. Maeda,et al.  Improvement of Pharmacological Properties of Protein-Drugs by Tailoring with Synthetic Polymers , 1988 .

[159]  H. Maeda,et al.  Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its actions by conjugation with lipophilic styrene-maleic acid copolymer. , 1987, Cancer research.

[160]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[161]  Barnett Rosenberg,et al.  Charles F. Kettring prize. Fundamental studies with cisplatin , 1985 .

[162]  S. Tashiro,et al.  Selective targeting of anti‐cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium , 1984, Cancer.

[163]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[164]  M. Mahmoudi,et al.  Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. , 2011, Advanced drug delivery reviews.

[165]  Hua Zhang,et al.  [Effects of rapamycin-loaded poly(lactic-co-glycolic) acid nanoparticles on distribution of cell cycle, expression of p27 protein, and proliferation of human umbilical arterial vascular smooth muscle cell in vitro]. , 2010, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.

[166]  Sudesh Kumar Yadav,et al.  Biodegradable polymeric nanoparticles based drug delivery systems. , 2010, Colloids and surfaces. B, Biointerfaces.

[167]  B. Aggarwal,et al.  Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. , 2009, The international journal of biochemistry & cell biology.

[168]  Hong Yang,et al.  Poly(D,L-lactide-co-glycolide) nanoparticles encapsulated fluorescent isothiocyanate and paclitaxol: preparation, release kinetics and anticancer effect. , 2009, Journal of nanoscience and nanotechnology.

[169]  Xiaohu Gao,et al.  Emerging application of quantum dots for drug delivery and therapy. , 2008, Expert opinion on drug delivery.

[170]  Ricky A. Sharma,et al.  Pharmacokinetics and pharmacodynamics of curcumin. , 2007, Advances in experimental medicine and biology.

[171]  Sha Jin,et al.  Nanoparticle‐Mediated Drug Delivery and Gene Therapy , 2007, Biotechnology progress.

[172]  S. Parveen,et al.  Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. , 2006, Clinical pharmacokinetics.

[173]  María J Vicent,et al.  Polymer conjugates: nanosized medicines for treating cancer. , 2006, Trends in biotechnology.

[174]  N. Zelcer,et al.  On the putative co‐transport of drugs by multidrug resistance proteins , 2006, FEBS letters.

[175]  E. Allémann,et al.  Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[176]  V. Labhasetwar,et al.  Nanosystems in Drug Targeting: Opportunities and Challenges , 2005 .

[177]  M N Ravi Kumar,et al.  Nano and microparticles as controlled drug delivery devices. , 2000, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[178]  F M Muggia,et al.  Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[179]  L. Murray,et al.  Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[180]  H. Maeda,et al.  Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. , 1998, Cancer research.

[181]  C. Ropert,et al.  Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. , 1992, Biomaterials.

[182]  D. Crommelin,et al.  Controlled release of bioactive agents from lactide/glycolide polymers , 1990 .

[183]  R. Langer,et al.  Biodegradable polymers as drug delivery systems , 1990 .

[184]  H. Maeda,et al.  Tumoritropic and lymphotropic principles of macromolecular drugs. , 1989, Critical reviews in therapeutic drug carrier systems.

[185]  B. Rosenberg.  Fundamental studies with cisplatin. , 1985, Cancer.